Clinical Trials Logo

Clinical Trial Summary

Aim:Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Drug information: - anti-PD1 antibody (Camrelizumab) - AG regimens:the standard first-line regimens for metastatic pancreatic cancer.


Clinical Trial Description

CPOG1210-07 is a prospective, randomized, double-blinded, multi-center clinical trial in China aiming to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. The anti-PD1 antibody(Camrelizumab) is a humanized monoclonal antibody which can specifically bind to PD-1 and block the interaction between PD-1 and its ligand (PD-L1), allowing T cells to recover the immune response against tumors. It is proved to be effective in certain cancers such as ovarian cancers and certification proved by Chinese Food and Drug Administration(CFDA) includes Hodgkin's lymphoma, non-small cell lung cancer, esophageal cancer and liver cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04674956
Study type Interventional
Source RenJi Hospital
Contact Liwei Wang, Doctor
Phone +86 16621086648
Email lwwang@163.com
Status Recruiting
Phase Phase 3
Start date March 4, 2021
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06155136 - RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
Not yet recruiting NCT05047991 - Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 2
Active, not recruiting NCT04469556 - Pancreatic Adenocarcinoma Signature Stratification for Treatment Phase 2
Completed NCT03504423 - Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Phase 3
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Withdrawn NCT04799431 - Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer Phase 1
Completed NCT03412799 - Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Phase 1
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT04467593 - Safety Study of Whole Body Hyperthermia for Advanced Cancer N/A
Recruiting NCT02959151 - A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy Phase 1/Phase 2
Completed NCT01652976 - Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Phase 2
Completed NCT04721301 - Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial Phase 1
Recruiting NCT04667403 - Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer N/A
Recruiting NCT06168812 - A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer Phase 2
Not yet recruiting NCT06076837 - The Seven Trial: Exploiting the Unfolded Protein Response Phase 1
Active, not recruiting NCT03984214 - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Phase 3
Recruiting NCT05254171 - Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Phase 2/Phase 3
Recruiting NCT04116073 - INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer Phase 2
Recruiting NCT04338763 - RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer Phase 1
Recruiting NCT06030622 - Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer Phase 1/Phase 2